Details:
A global Phase 2/3 study in up to 270 patients hospitalized with severe COVID-19 pneumonia, and a U.S. Phase 2 study in up to 40 patients, are ongoing with opaganib, a novel sphingosine kinase-2 selective inhibitor with dual anti-inflammatory and anti-viral properties.
Lead Product(s): Opaganib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Yeliva
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: State of Pennsylvania
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Funding September 03, 2020